Skip to main content Accessibility help
×
Hostname: page-component-788cddb947-w95db Total loading time: 0 Render date: 2024-10-09T22:39:40.418Z Has data issue: false hasContentIssue false

Red Cell Alloimmunization

from Section 2: - Fetal Disease: Pathogenesis and Treatment

Published online by Cambridge University Press:  21 October 2019

Mark D. Kilby
Affiliation:
University of Birmingham
Anthony Johnson
Affiliation:
University of Texas Medical School at Houston
Dick Oepkes
Affiliation:
Leids Universitair Medisch Centrum
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Fetal Therapy
Scientific Basis and Critical Appraisal of Clinical Benefits
, pp. 91 - 109
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Bowman, JM, Pollock, JM, Penston, LE. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang. 1986; 51: 117–21.CrossRefGoogle ScholarPubMed
Nederlandse Vereniging voor Obstetrie & Gynaecologie (NVOG) (2009). Erytrocytenimmunisatie en zwangerschap: Versie 2.1. https://www.nvog.nl/wp-content/uploads/2018/03/Erytrocytenimmunisatie-en-zwangerschap_.pdfGoogle Scholar
Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. Obstet Gynecol. 2017; 130: e57–70.Google Scholar
Qureshi, H, Massey, E, Kirwan, D, Davies, T, Robson, S, White, J, Jones, J, Allard, S, British Society for Haematology. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med. 2014; 24: 820.CrossRefGoogle ScholarPubMed
Levine, P. Serological factors as possible causes in spontaneous abortions. J Hered. 1943; 34: 7180.CrossRefGoogle Scholar
Zwiers, C, Koelewijn, JM, Vermij, L, van Sambeeck, J, Oepkes, D, de Haas, M, van der Schoot, CE. ABO incompatibility and RhIG immunoprophylaxis protect against non-D alloimmunization by pregnancy. Transfusion. 2018; 58: 1611–17.CrossRefGoogle ScholarPubMed
Royal College of Obstetricians and Gynaecologists (2014). Green-top Guideline 65: The Management of Women with Red Cell Antibodies during Pregnancy. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg65Google Scholar
ACOG. Practice Bulletin No. 192: Management of alloimmunization during pregnancy. Obstet Gynecol. 2018; 131: e82–90.Google Scholar
Rijksinstituut voor Volksgezondheid en Milieu (RIVM) (2018). Draaiboek prenatale screening infectieziekten en erytrocytenimmunisatie: Versie 6.0. https://www.rivm.nl/documenten/draaiboek-prenatale-screening-infectieziekten-en-erytrocytenimmunisatieGoogle Scholar
National Blood Authority Australia (2015). Patient Blood Management Guidelines: Module 5 Obstetrics and Maternity. https://www.blood.gov.au/pbm-module-5Google Scholar
Koelewijn, JM, de Haas, M, Vrijkotte, TG, Bonsel, GJ, van der Schoot, CE. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion. 2008; 48: 1721–9.CrossRefGoogle ScholarPubMed
Mayne, S, Parker, JH, Harden, TA, Dodds, SD, Beale, JA. Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme. BMJ. 1997; 315: 1588.Google Scholar
van der Ploeg, CPB, Schönbeck, Y, Oomen, P, Vos, K. Prenatale Screening Infectieziekten en Erytrocytenimmunisatie (PSIE) Procesmonitor 2015. Bilthoven: RIVM, TNO, 2017.Google Scholar
Hendrickson, JE, Delaney, M. Hemolytic Disease of the fetus and newborn: modern practice and future Investigations. Transfus Med Rev. 2016; 30: 159–64.Google Scholar
Scheffer, PG, van der Schoot, CE, Page-Christiaens, GC, de Haas, M. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG. 2011; 118: 1340–8.Google Scholar
Slootweg, YM, Lindenburg, IT, Koelewijn, JM, van Kamp, IL, Oepkes, D, de Haas, M. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. Am J Obstet Gynecol. 2018; 219: 393.e1393.e8.CrossRefGoogle ScholarPubMed
van Dijk, BA, Dooren, MC, Overbeeke, MA. Red cell antibodies in pregnancy: there is no ‘critical titre’. Transfus Med. 1995; 5: 199202.Google Scholar
Oepkes, D, van Kamp, IL, Simon, MJ, Mesman, J, Overbeeke, MA, Kanhai, HH. Clinical value of an antibody-dependent cell-mediated cytotoxicity assay in the management of Rh D alloimmunization. Am J Obstet Gynecol. 2001; 184: 1015–20.Google Scholar
Zwiers, C, van Kamp, I, Oepkes, D, Lopriore, E. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn – review on current management and outcome. Expert Rev Hematol. 2017; 10: 337–44.Google Scholar
Mari, G, Deter, RL, Carpenter, RL, Rahman, F, Zimmerman, R, Moise, KJ Jr., et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative group for Doppler assessment of the blood velocity in anemic fetuses. N Engl J Med. 2000; 342: 914.Google Scholar
Zimmerman, R, Carpenter, RJ Jr., Durig, P, Mari, G. Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation: a prospective multicentre trial with intention-to-treat. BJOG. 2002; 109: 746–52.Google Scholar
Oepkes, D, Brand, R, Vandenbussche, FP, Meerman, RH, Kanhai, HH. The use of ultrasonography and Doppler in the prediction of fetal haemolytic anaemia: a multivariate analysis. Br J Obstet Gynaecol. 1994; 101: 680–4.Google Scholar
Chitkara, U, Wilkins, I, Lynch, L, Mehalek, K, Berkowitz, RL. The role of sonography in assessing severity of fetal anemia in Rh- and Kell-isoimmunized pregnancies. Obstet Gynecol. 1988; 71: 393–8.Google Scholar
Dukler, D, Oepkes, D, Seaward, G, Windrim, R, Ryan, G. Noninvasive tests to predict fetal anemia: a study comparing Doppler and ultrasound parameters. Am J Obstet Gynecol. 2003; 188: 1310–14.Google Scholar
Oepkes, D, Seaward, PG, Vandenbussche, FP, Windrim, R, Kingdom, J, Beyene, J, Kanhai, HH, Ohlsson, A, Ryan, G, DIAMOND Study Group. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med. 2006; 355: 156–64.CrossRefGoogle ScholarPubMed
Bang, J, Bock, JE, Trolle, D. Ultrasound-guided fetal intravenous transfusion for severe rhesus haemolytic disease. BMJ (Clin Res Ed). 1982; 284: 373–4.Google Scholar
Moise, KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. 2008; 112: 164–76.Google Scholar
Nicolaides, KH, Soothill, PW, Clewell, WH, Rodeck, CH, Mibashan, RS, Campbell, S. Fetal haemoglobin measurement in the assessment of red cell isoimmunisation. Lancet. 1988; 1: 1073–5.Google Scholar
Society for Maternal-Fetal Medicine, Mari, G, Norton, ME, Stone, J, Berghella, V, Sciscione, AC, Tate, D, Schenone, MH. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia – diagnosis and management. Am J Obstet Gynecol. 2015; 212: 697710.CrossRefGoogle Scholar
Adama van Scheltema, PN, Borkent, S, Sikkel, E, Oepkes, D, Vandenbussche, FP. Fetal brain hemodynamic changes in intrauterine transfusion: influence of needle puncture site. Fetal Diagn Ther. 2009; 26: 131–3.Google Scholar
Moise, KJ Jr., Carpenter, RJ Jr., Kirshon, B, Deter, RL, Sala, JD, Cano, LE. Comparison of four types of intrauterine transfusion: effect on fetal hematocrit. Fetal Ther. 1989; 4: 126–37.CrossRefGoogle ScholarPubMed
Zwiers, C, Lindenburg, ITM, Klumper, FJ, de Haas, M, Oepkes, D, Van Kamp, IL. Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound Obstet Gynecol. 2017; 50: 180–6.CrossRefGoogle ScholarPubMed
Detti, L, Oz, U, Guney, I, Ferguson, JE, Bahado-Singh, RO, Mari, G. Doppler ultrasound velocimetry for timing the second intrauterine transfusion in fetuses with anemia from red cell alloimmunization. Am J Obstet Gynecol. 2001; 185: 1048–51.CrossRefGoogle ScholarPubMed
Weiner, CP, Williamson, RA, Wenstrom, KD, Sipes, SL, Widness, JA, Grant, SS, Estle, L. Management of fetal hemolytic disease by cordocentesis. II. Outcome of treatment. Am J Obstet Gynecol. 1991; 165: 1302–7.Google Scholar
Scheier, M, Hernandez-Andrade, E, Fonseca, EB, Nicolaides, KH. Prediction of severe fetal anemia in red blood cell alloimmunization after previous intrauterine transfusions. Am J Obstet Gynecol. 2006; 195: 1550–6.Google Scholar
Tiblad, E, Kublickas, M, Ajne, G, Bui, TH, Ek, S, Karlsson, A, Wikman, A, Westgren, M. Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. Fetal Diagn Ther. 2011; 30: 266–73.CrossRefGoogle ScholarPubMed
Pasman, SA, Claes, L, Lewi, L, Van Schoubroeck, D, Debeer, A, Emonds, M, Geuten, E, De Catte, L, Devlieger, R. Intrauterine transfusion for fetal anemia due to red blood cell alloimmunization: 14 years experience in Leuven. Facts Views Vis Obgyn. 2015; 7: 129–36.Google Scholar
Sainio, S, Nupponen, I, Kuosmanen, M, Aitokallio-Tallberg, A, Ekholm, E, Halmesmäki, E, Orden, MR, Palo, P, Raudaskoski, T, Tekay, A, Tuimala, J, Uotila, J, Stefanovic, V. Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study. Acta Obstet Gynecol Scand. 2015; 94: 383–90.Google Scholar
Lindenburg, IT, Wolterbeek, R, Oepkes, D, Klumper, FJ, Vandenbussche, FP, van Kamp, IL. Quality control for intravascular intrauterine transfusion using cumulative sum (CUSUM) analysis for the monitoring of individual performance. Fetal Diagn Ther. 2011; 29: 307–14.CrossRefGoogle ScholarPubMed
Zwiers, C, Oepkes, D, Lopriore, E, Klumper, FJ, De Haas, M, van Kamp, IL. The near disappearance of fetal immune hydrops in relation to current state‐of‐the‐art management of red cell alloimmunization. Prenat Diagn. 2018; 38: 943–50.CrossRefGoogle Scholar
van Kamp, IL, Klumper, FJ, Bakkum, RS, Oepkes, D, Meerman, RH, Scherjon, SA, Kanhai, HH. The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment. Am J Obstet Gynecol. 2001; 185: 668–73.CrossRefGoogle ScholarPubMed
Ree, IMC, Smits-Wintjens, V, van der Bom, JG, van Klink, JMM, Oepkes, D, Lopriore, E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017; 10: 607–16.Google Scholar
Lindenburg, IT, Smits-Wintjens, VE, van Klink, JM, Verduin, E, van Kamp, IL, Walther, FJ, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol. 2012; 206: 141. e1–8.CrossRefGoogle ScholarPubMed
Zwiers, C, van der Bom, JG, van Kamp, IL, van Geloven, N, Lopriore, E, Smoleniec, J, et al. Postponing Early Intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol. 2018; 219: e1291. e9.Google Scholar
Bowman, JM. Antenatal suppression of Rh alloimmunization. Clin Obstet Gynecol. 1991; 34: 296303.Google Scholar
Giannina, G, Moise, KJ Jr., Dorman, K. A simple method to estimate volume for fetal intravascular transfusions. Fetal Diagn Ther. 1998; 13: 94–7.Google Scholar

References

Dreyfus, M, Kaplan, C, Verdy, E, Schlegel, N, Durand-Zaleski, I, Tchernia, G. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood. 1997; 89: 4402–6.Google Scholar
Sola-Visner, M, Saxonhouse, MA, Brown, RE. Neonatal thrombocytopenia: what we do and don’t know. Early Hum Dev. 2008; 84: 499506.Google Scholar
Winkelhorst, D, Kamphuis, MM, de Kloet, LC, Zwaginga, JJ, Oepkes, D, Lopriore, E. Severe bleeding complications other than intracranial hemorrhage in neonatal alloimmune thrombocytopenia: a case series and review of the literature. Transfusion. 2016; 56: 1230–5.CrossRefGoogle ScholarPubMed
Tiller, H, Kamphuis, MM, Flodmark, O, Papadogiannakis, N, David, AL, Sainio, S, et al. Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open. 2013; 3: e002490.CrossRefGoogle ScholarPubMed
Campbell, S, Swann, HR, Seif, MW, Kimber, SJ, Aplin, JD. Cell adhesion molecules on the oocyte and preimplantation human embryo. Hum Reprod. 1995; 10: 1571–8.Google Scholar
Ohto, H. [Neonatal alloimmune thrombocytopenia]. Nihon Rinsho. 1997; 55: 2310–14.Google Scholar
Ohto, H, Miura, S, Ariga, H, Ishii, T, Fujimori, K, Morita, S. The natural history of maternal immunization against foetal platelet alloantigens. Transfus Med. 2004; 14: 399408.Google Scholar
Kunishima, S, Hayakawa, A, Fujita, K, Saito, H. Transient macrothrombocytopenia associated with maternal-neonatal HPA-21bw incompatibility. Thromb Res. 2013; 131: e286–8.Google Scholar
Shivdasani, RA, Rosenblatt, MF, Zucker-Franklin, D, Jackson, CW, Hunt, P, Saris, CJ, Orkin, SH. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell. 1995; 81: 695704.CrossRefGoogle ScholarPubMed
van Gils, JM, Stutterheim, J, van Duijn, TJ, Zwaginga, JJ, Porcelijn, L, de Haas, M, Hordijk, PL. HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity. Mol Immunol. 2009; 46: 406–15.Google Scholar
Yougbaré, I, Lang, S, Yang, H, Chen, P, Zhao, X, Tai, WS, et al. Maternal anti-platelet beta3 integrins impair angiogenesis and cause intracranial hemorrhage. J Clin Invest. 2015; 125: 1545–56.Google Scholar
Santoso, S, Wihadmadyatami, H, Bakchoul, T, Werth, S, Al-Fakhri, N, Bein, G, et al. Antiendothelial alphavbeta3 antibodies are a major cause of intracranial bleeding in fetal/neonatal alloimmune thrombocytopenia. Arterioscler Thromb Vasc Biol. 2016; 36: 1517–24.Google Scholar
Tiller, H, Killie, MK, Husebekk, A, Skogen, B, Ni, H, Kjeldsen-Kragh, J, Øian, P. Platelet antibodies and fetal growth: maternal antibodies against fetal platelet antigen 1a are strongly associated with reduced birthweight in boys. Acta Obstet Gynecol Scand. 2012; 91: 7986.Google Scholar
Murphy, MF, Hambley, H, Nicolaides, K, Waters, AH. Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalus. Prenat Diagn. 1996; 16: 1152–5.Google Scholar
Althaus, J, Weir, EG, Askin, F, Kickler, TS, Blakemore, K. Chronic villitis in untreated neonatal alloimmune thrombocytopenia: an etiology for severe early intrauterine growth restriction and the effect of intravenous immunoglobulin therapy. Am J Obstet Gynecol. 2005; 193: 1100–4.Google Scholar
Pereira, J, Cretney, C, Aster, RH. Variation of class I HLA antigen expression among platelet density cohorts: a possible index of platelet age? Blood. 1988; 71: 516–19.Google Scholar
Masson, E, Vidal, C, Deschamps, M, Bongain, S, Thevenin, C, Dupont, I, et al. Incidence and risk factors of anti-HLA immunization after pregnancy. Hum Immunol. 2013; 74: 946–51.CrossRefGoogle Scholar
Sharon, R, Amar, A. Maternal anit-HLA antibodies and neonatal thrombocytopenia. Lancet. 1981; 1: 1313.Google Scholar
Vilches, M, Nieto, A. Analysis of Pregnancy-Induced Anti-HLA Antibodies Using Luminex Platform. Transplant Proc. 2015; 47: 2608–10.Google Scholar
Chow, MP, Sun, KJ, Yung, CH, Hu, HY, Tzeng, JL, Lee, TD. Neonatal alloimmune thrombocytopenia due to HLA-A2 antibody. Acta Haematol. 1992; 87: 153–5.Google Scholar
De Tar, MW, Klohe, E, Grosset, A, Rau, T. Neonatal alloimmune thrombocytopenia with HLA alloimmunization: case report with immunohematologic and placental findings. Pediatr Dev Pathol. 2002; 5: 200–5.Google Scholar
del Rosario, ML, Fox, ER, Kickler, TS, Kao, KJ. Neonatal alloimmune thrombocytopenia associated with maternal anti-HLA antibody: a case report. J Pediatr Hematol Oncol. 1998; 20: 252–6.Google Scholar
Gramatges, MM, Fani, P, Nadeau, K, Pereira, S, Jeng, MR. Neonatal alloimmune thrombocytopenia and neutropenia associated with maternal human leukocyte antigen antibodies. Pediatr Blood Cancer. 2009; 53: 97–9.CrossRefGoogle ScholarPubMed
Hutchinson, AL, Dennington, PM, Holdsworth, R, Downe, L. Recurrent HLA-B56 mediated neonatal alloimmune thrombocytopenia with fatal outcomes. Transfus Apher Sci. 2015; 52: 311–13.Google Scholar
Moncharmont, P, Dubois, V, Obegi, C, Vignal, M, Mérieux, Y, Gebuhrer, L, Rigal, D. HLA antibodies and neonatal alloimmune thrombocytopenia. Acta Haematol. 2004; 111: 215–20.Google Scholar
Onishi, S, Okubo, S, Matsuzaki, T, Ishida, T, Yasunaga, K. [Report of two cases of neonatal alloimmune thrombocytopenia caused by anti-HLA antibody, and their screening using umbilical cord blood]. Rinsho Ketsueki. 1992; 33: 42–7.Google Scholar
Saito, S, Ota, M, Komatsu, Y, Ota, S, Aoki, S, Koike, K, et al. Serologic analysis of three cases of neonatal alloimmune thrombocytopenia associated with HLA antibodies. Transfusion. 2003; 43: 908–17.Google Scholar
Sasaki, M, Yagihashi, A, Kobayashi, D, Watanabe, N, Fujikawa, T, Chiba, S, et al. Neonatal alloimmune thrombocytopenia due to anti-human leukocyte antigen antibody: a case report. Pediatr Hematol Oncol. 2001; 18: 519–24.Google Scholar
Thude, H, Schorner, U, Helfricht, C, Loth, M, Maak, B, Barz, D. Neonatal alloimmune thrombocytopenia caused by human leucocyte antigen-B27 antibody. Transfus Med. 2006; 16: 143–9.Google Scholar
Starcevic, M, Tomicic, M, Malenica, M, Zah-Matakovic, V. Neonatal alloimmune thrombocytopenia caused by anti-HLA-A24 alloantibodies. Acta Paediatr. 2010; 99: 630–2.Google Scholar
Winkelhorst, D, Porcelijn, L, van de Weerd, JME, Huiskes, E, Muizelaar, E, Lardy, NM, et al. HLA class I antibodies in FNAIT. (Poster). 14th European Symposium on Platelet and Granulocyte Immunobiology. Stockholm, 2016.Google Scholar
Wu, S, Maslanka, K, Gorski, J. An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding: a model for unidirectional alloimmune responses. J Immunol. 1997; 158: 3221–6.Google Scholar
Burrows, RF, Kelton, JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. New Engl J Med. 1993; 329: 1463–6.Google Scholar
Kamphuis, MM, Paridaans, NP, Porcelijn, L, Lopriore, E, Oepkes, D. Incidence and consequences of neonatal alloimmune thrombocytopenia: a systematic review. Pediatrics. 2014; 133: 715–21.CrossRefGoogle ScholarPubMed
Kamphuis, MM, Paridaans, N, Porcelijn, L, De Haas, M, Van Der Schoot, CE, Brand, A, Bonsel, GJ, Oepkes, D. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG. 2010; 117: 1335–43.Google Scholar
Davoren, A, McParland, P, Barnes, CA, Murphy, WG. Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases. J Clin Pathol. 2002; 55: 289–92.Google Scholar
Spencer, JA, Burrows, RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol. 2001; 41: 4555.Google Scholar
Kiefel, V, Santoso, S, Weisheit, M, Mueller-Eckhardt, C. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987; 70: 1722–6.Google Scholar
Scheffer, PG, Ait Soussan, A, Verhagen, OJ, Page-Christiaens, GC, Oepkes, D, de Haas, M, Van Der Schoot, CE. Noninvasive fetal genotyping of human platelet antigen-1a. BJOG. 2011; 118: 1392–5.Google Scholar
Wienzek-Lischka, S, Krautwurst, A, Fröhner, V, Hackstein, H, Gattenlöhner, S, Bräuninger, A, et al. Noninvasive fetal genotyping of human platelet antigen-1a using targeted massively parallel sequencing. Transfusion. 2015; 55: 1538–44.Google Scholar
Bessos, H, Turner, M, Urbaniak, SJ. Is there a relationship between anti-HPA-1a concentration and severity of neonatal alloimmune thrombocytopenia? Immunohematology. 2005; 21: 102–9.Google Scholar
Sonneveld, ME, Natunen, S, Sainio, S, Koeleman, CA, Holst, S, Dekkers, G, et al. Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia. Br J Haematol. 2016; 174: 310–20.CrossRefGoogle ScholarPubMed
Radder, CM, Brand, A, Kanhai, HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vox Sang. 2003; 84: 318–25.Google Scholar
Winkelhorst, D, Murphy, MF, Greinacher, A, Shehata, N, Bakchoul, T, Massey, E, et al. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. Blood. 2017; 129: 1538–47.Google Scholar
Bussel, JB, Berkowitz, RL, McFarland, JG, Lynch, L, Chitkara, U. Antenatal treatment of neonatal alloimmune thrombocytopenia. New Engl J Med. 1988; 319: 1374–8.Google Scholar
Daffos, F, Forestier, F, Muller, JY, Reznikoff-Etievant, M, Habibi, B, Capella-Pavlovsky, M, et al. Prenatal treatment of alloimmune thrombocytopenia. Lancet. 1984; 2: 632.Google Scholar
Sainio, S, Teramo, K, Kekomaki, R. Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia. Transfus Med. 1999; 9: 321–30.Google Scholar
Kamphuis, M, Paridaans, N, Winkelhorst, D, Wikman, A, Tiblad, E, Lopriore, E, et al. Lower-dose intravenous immunoglobulins for the treatment of fetal and neonatal alloimmune thrombocytopenia: a cohort study. Transfusion. 2016; 56: 2308–13.Google Scholar
Bussel, JB, Berkowitz, RL, Hung, C, Kolb, EA, Wissert, M, Primiani, A, et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol. 2010; 203: 135.e1–14.Google Scholar
Berkowitz, RL, Lesser, ML, McFarland, JG, Wissert, M, Primiani, A, Hung, C, Bussel, JB. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol. 2007; 110: 249–55.Google Scholar
Radder, CM, de Haan, MJ, Brand, A, Stoelhorst, GM, Veen, S, Kanhai, HH. Follow up of children after antenatal treatment for alloimmune thrombocytopenia. Early Hum Dev. 2004; 80: 6576.Google Scholar
Kaplan, C, Murphy, MF, Kroll, H, Waters, AH. Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids – more questions than answers. European Working Group on FMAIT. Br J Haematol. 1998; 100: 62–5.Google Scholar
Bertrand, G, Drame, M, Martageix, C, Kaplan, C. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia. Blood. 2011; 117: 3209–13.CrossRefGoogle ScholarPubMed
Berkowitz, RL, Kolb, EA, McFarland, JG, Wissert, M, Primani, A, Lesser, M, Bussel, JB. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol. 2006; 107: 91–6.Google Scholar
Bussel, JB, Berkowitz, RL, Lynch, L, Lesser, ML, Paidas, MJ, Huang, CL, McFarland, JG. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol. 1996; 174: 1414–23.Google Scholar
Wenstrom, KD, Weiner, CP, Williamson, RA. Antenatal treatment of fetal alloimmune thrombocytopenia. Obstet Gynecol. 1992; 80: 433–5.Google Scholar
Lynch, L, Bussel, JB, McFarland, JG, Chitkara, U, Berkowitz, RL. Antenatal treatment of alloimmune thrombocytopenia. Obstet Gynecol. 1992; 80: 6771.Google ScholarPubMed
de Haas, M, Thurik, FF, Koelewijn, JM, van der Schoot, CE. Haemolytic disease of the fetus and newborn. Vox Sang. 2015; 109: 99113.Google Scholar
Zwiers, C, Lindenburg, ITM, Klumper, FJ, de Haas, M, Oepkes, D, Van Kamp, IL. Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound Obstet Gynecol. 2017; 50: 180–6.Google Scholar
Bowman, J. Thirty-five years of Rh prophylaxis. Transfusion. 2003; 43: 1661–6.Google Scholar
Tiller, H, Killie, MK, Chen, P, Eksteen, M, Husebekk, A, Skogen, B, Kjeldsen-Kragh, J, Ni, H. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion. 2012; 52: 1446–57.Google Scholar
Ghevaert, C, Wilcox, DA, Fang, J, Armour, KL, Clark, MR, Ouwehand, WH, Williamson, LM. Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. J Clin Invest. 2008; 118: 2929–38.Google Scholar
Ghevaert, C, Herbert, N, Hawkins, L, Grehan, N, Cookson, P, Garner, SF, et al. Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers. Blood. 2013; 122: 313–20.Google Scholar
Kjeldsen-Kragh, J, Killie, MK, Tomter, G, Golebiowska, E, Randen, I, Hauge, R, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007; 110: 833–9.Google Scholar
van den Akker, ESA, Oepkes, D, Brand, A, Kanhai, HHH. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia? BJOG. 2006; 113: 781–3.Google Scholar
Roberts, I, Murray, NA. Neonatal thrombocytopenia: causes and management. Arch Dis Child Fetal Neonatal Ed. 2003; 88: F359–64.Google Scholar
Gunnink, SF, Vlug, R, Fijnvandraat, K, van der Bom, JG, Stanworth, SJ, Lopriore, E. Neonatal thrombocytopenia: etiology, management and outcome. Expert Rev Hematol. 2014; 7: 387–95.Google Scholar
Ghevaert, C, Campbell, K, Walton, J, Smith, GA, Allen, D, Williamson, LM, et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion. 2007; 47: 901–10.Google Scholar
Inder, TE, Perlman, M, Volpe, JJ. Intracranial Hemorrhage: Subdural, Subarachnoid, Intraventricular (Term Infant), Miscellaneous. In Volpe, JJ, Neurology of the Newborn. 6th Edition ed. Philadelphia: Elsevier, 2018.Google Scholar
Vinekar, A, Hegde, K, Gilbert, C, Braganza, S, Pradeep, M, Shetty, R, Shetty, KB. Do platelets have a role in the pathogenesis of aggressive posterior retinopathy of prematurity? Retina. 2010; 30: S20–3.Google Scholar
Stanworth, SJ, Clarke, P, Watts, T, Ballard, S, Choo, L, Morris, T, Murphy, MF, Roberts, I, Platelets and Neonatal Transfusion Study Group. Prospective, observational study of outcomes in neonates with severe thrombocytopenia. Pediatrics. 2009; 124: e826–34.Google Scholar
Murray, NA, Roberts, IA. Circulating megakaryocytes and their progenitors in early thrombocytopenia in preterm neonates. Pediatr Res. 1996; 40: 112–19.Google Scholar
Blajchman, MA, Ali, AM, Richardson, HL. Bacterial contamination of cellular blood components. Vox Sang. 1994; 67 (Suppl. 3): 2533.Google Scholar
Murphy, MF, Williamson, LM. Antenatal screening for fetomaternal alloimmune thrombocytopenia: an evaluation using the criteria of the UK National Screening Committee. Br J Haematol. 2000; 111: 726–32.Google Scholar
Kiefel, V, Bassler, D, Kroll, H, Paes, B, Giers, G, Ditomasso, J, et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood. 2006; 107: 3761–3.CrossRefGoogle ScholarPubMed
Chen, P, Li, C, Lang, S, Zhu, G, Reheman, A, Spring, CM, Freedman, J, Ni, H. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood. 2010; 116: 3660–8.Google ScholarPubMed
Sidiropoulos, D, Straume, B. The treatment of neonatal isoimmune thrombocytopenia with intravenous immunoglobin (IgG i.v.). Blut. 1984; 48: 383–6.Google Scholar
Derycke, M, Dreyfus, M, Ropert, JC, Tchernia, G. Intravenous immunoglobulin for neonatal isoimmune thrombocytopenia. Arch Dis Child. 1985; 60: 667–9.Google Scholar
Winkelhorst, D, Kamphuis, MM, Steggerda, SJ, Rijken, M, Oepkes, D, Lopriore, E, van Klink, JMM. Perinatal outcome and long-term neurodevelopment after intracranial haemorrhage due to fetal and neonatal alloimmune thrombocytopenia. Fetal Diagn Ther. 2019; 45: 184–91.Google Scholar
Winkelhorst, D, Oostweegel, M, Porcelijn, L, Middelburg, RA, Zwaginga, JJ, Oepkes, D, et al. Treatment and outcomes of fetal/neonatal alloimmune thrombocytopenia: a nationwide cohort study in newly detected cases. Br J Haematol. 2019; 184: 1026–9.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×